Iya Khalil, PhD, discusses Merck & Co.’s approach to artificial intelligence (AI), and success in applying the technology, ...

Leading companies spent $1.4 billion upfront on licensing deals and embarked on vast R&D programs. Clinical setbacks mean ...

SpringWorks Therapeutics Inc. (NASDAQ: SWTX) is one of the best biotech stocks to invest in now. On June 20, SpringWorks ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small to justify the costs. Neither Kisunla ...

In a first for the bloc, Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing ...

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the ...

During a live event, Hari Deshpande, MD, and participants discussed the DeFi trial and the management of nirogacestat in ...

Summit Therapeutics (SMMT) stock, a potential rival for Merck (MRK) traded lower as Leerink Partners started its coverage with a Sell-equivalent rating. Read more here.

BNT327, a next-generation bispecific antibody candidate, targets PD-L1 and VEGF-A. Per the terms, BMY will make an upfront ...

In April, Germany-based Merck KGaA announced that it will acquire SpringWorks Therapeutics, Inc. for $3.9 billion to expand business in the United States.

Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines.